NEW YORK, Aug. 5, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cell therapy market, today announced that the Company will visit the NASDAQ MarketSite in Times Square and ring the Opening Bell on Wednesday, August 7, 2013. Dr. Robin L. Smith, Chairman and CEO, and others from the NeoStem senior management will perform the honorary ringing of the bell along with other members of the team, some board members and company investors.
The bell ringing is in celebration of the switch of the Company's listing to the NASDAQ Capital Market from NYSE MKT effective with the start of trading today, August 5, 2013. NeoStem will continue to trade under its existing ticker symbol "NBS".
"We are excited to commemorate this new beginning for NeoStem on NASDAQ," said Dr. Robin L. Smith. "NeoStem's move to NASDAQ aligns with the Company's plans to grow and expand its cellular therapy-based R&D platform and contract manufacturing capabilities, both in the US and internationally. We believe that NASDAQ will provide our Company with enhanced exposure, while at the same time providing investors with the best prices, the fastest execution and lowest cost per trade. Additionally, we believe that our transfer to the NASDAQ will enhance our public visibility to institutional shareholders. As the world's largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. We are proud to be joining fellow cell therapy industry companies such as Celgene Corporation, Harvard Bioscience Inc., Osiris Therapeutics, Inc., Mesoblast Limited, Stemline Therapeutics, Inc., Verastem, Inc. and Shire PLC on the NASDAQ."Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Wednesday, August 7, 2013 – 9:15 a.m. to 9:30 a.m. ET Webcast: A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx . About NeoStem, Inc. NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.